Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2007

01.09.2007 | Epidemiology

Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival

verfasst von: Aesun Shin, Zefang Ren, Xiao-Ou Shu, Qiuyin Cai, Yu-Tang Gao, Wei Zheng

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

The level of circulating insulin-like growth factor 1 (IGF-I) has been shown to be positively associated with breast cancer risk. The expression patterns of the IGF-I and its receptor IGFIR genes in breast tissues and their association with breast cancer survival remain unclear. In the present study, we quantified the mRNA levels of the IGF-I and IGFIR genes in both benign and malignant breast tumor tissues and their adjacent normal tissues. We then evaluated whether the expression patterns of these genes in breast cancer tissues are related to breast cancer survival. Included in the study were samples from 508 patients diagnosed with primary breast cancer, and 206 patients diagnosed with benign breast disease (BBD). Patients with BBD had a significantly higher IGF-I gene expression than patients with breast cancer in both tumor and adjacent non-neoplastic tissues. Among BBD patients, mRNA levels of the IGF-I gene were similar between tumor and tumor adjacent tissues. In cancer patients, however, the expression levels of these genes were substantially higher in tumor adjacent tissues than in tumor tissues. Patients with a high expression of the IGF-I gene in cancer tissues tended to have more favorable overall and disease-free survival. Our findings suggest that the expression of IGF-I and IGFIR genes may undergo substantial change over the course of breast tumorigenesis, and the pattern of changes may be associated with breast cancer prognosis.
Literatur
1.
Zurück zum Zitat Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489PubMedCrossRef Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489PubMedCrossRef
2.
Zurück zum Zitat Grimberg A (2003) Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2:630–635PubMed Grimberg A (2003) Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2:630–635PubMed
3.
Zurück zum Zitat Neuenschwander S, Roberts CT Jr, LeRoith D (1995) Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136:4298–4303PubMedCrossRef Neuenschwander S, Roberts CT Jr, LeRoith D (1995) Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136:4298–4303PubMedCrossRef
4.
Zurück zum Zitat Renehan AG, Zwahlen M, Minder C, O’dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRef Renehan AG, Zwahlen M, Minder C, O’dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRef
5.
Zurück zum Zitat Chong YM, Williams SL, Elkak A, Sharma AK, Mokbel K (2006) Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res 26:167–173PubMed Chong YM, Williams SL, Elkak A, Sharma AK, Mokbel K (2006) Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res 26:167–173PubMed
6.
Zurück zum Zitat Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509–517PubMedCrossRef Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509–517PubMedCrossRef
7.
Zurück zum Zitat Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183:412–417PubMedCrossRef Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183:412–417PubMedCrossRef
8.
Zurück zum Zitat Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Noguchi M, Nakamura S, Matsubara F (1990) Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 10:1115–1126PubMed Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Noguchi M, Nakamura S, Matsubara F (1990) Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 10:1115–1126PubMed
9.
Zurück zum Zitat Nardon E, Buda I, Stanta G, Buratti E, Fonda M, Cattin L (2003) Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer. J Clin Pathol 56:599–604PubMedCrossRef Nardon E, Buda I, Stanta G, Buratti E, Fonda M, Cattin L (2003) Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer. J Clin Pathol 56:599–604PubMedCrossRef
10.
Zurück zum Zitat Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736–3740PubMed Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736–3740PubMed
11.
Zurück zum Zitat Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D (2000) Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89:506–513PubMedCrossRef Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D (2000) Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89:506–513PubMedCrossRef
12.
Zurück zum Zitat Voskuil DW, Bosma A, Vrieling A, Rookus MA, ‘t Veer LJ (2004) Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 84:225–233PubMedCrossRef Voskuil DW, Bosma A, Vrieling A, Rookus MA, ‘t Veer LJ (2004) Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 84:225–233PubMedCrossRef
13.
Zurück zum Zitat Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, Sellers TA, Kushi LH, Ruan Z, Bostick RM, Jin F, Zheng W (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the shanghai breast cancer study. Int J Cancer 87:295–300PubMedCrossRef Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, Sellers TA, Kushi LH, Ruan Z, Bostick RM, Jin F, Zheng W (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the shanghai breast cancer study. Int J Cancer 87:295–300PubMedCrossRef
14.
Zurück zum Zitat Schnitt S, Connolly J (1999) Pathology of benign breast disorders. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast. Lippincott Williams & Wilkins, Philadelphia, pp 75–93 Schnitt S, Connolly J (1999) Pathology of benign breast disorders. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast. Lippincott Williams & Wilkins, Philadelphia, pp 75–93
15.
Zurück zum Zitat Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, Ruan ZX, Gao YT, Zheng W (2005) Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65:5015–5019PubMedCrossRef Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, Ruan ZX, Gao YT, Zheng W (2005) Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65:5015–5019PubMedCrossRef
16.
Zurück zum Zitat Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, Yang G, Jin F, Zheng W (2004) Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 64:836–839PubMedCrossRef Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, Yang G, Jin F, Zheng W (2004) Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 64:836–839PubMedCrossRef
17.
Zurück zum Zitat Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME (1991) Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:4978–4985PubMed Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME (1991) Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:4978–4985PubMed
18.
Zurück zum Zitat Foekens JA, Portengen H, Van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG (1989) Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009PubMed Foekens JA, Portengen H, Van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG (1989) Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009PubMed
19.
Zurück zum Zitat Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35:1537–1542PubMedCrossRef Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35:1537–1542PubMedCrossRef
20.
Zurück zum Zitat Bonneterre J, Peyrat JP, Beuscart R, Demaille A (1990) Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50:6931–6935PubMed Bonneterre J, Peyrat JP, Beuscart R, Demaille A (1990) Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50:6931–6935PubMed
21.
Zurück zum Zitat Berns EM, Klijn JG, Van Staveren IL, Portengen H, Foekens JA (1992) Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036–1039PubMed Berns EM, Klijn JG, Van Staveren IL, Portengen H, Foekens JA (1992) Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036–1039PubMed
Metadaten
Titel
Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival
verfasst von
Aesun Shin
Zefang Ren
Xiao-Ou Shu
Qiuyin Cai
Yu-Tang Gao
Wei Zheng
Publikationsdatum
01.09.2007
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9427-1

Weitere Artikel der Ausgabe 1/2007

Breast Cancer Research and Treatment 1/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.